Metabolomics of Obstructive Sleep Apnea

Description

This is an R01 funded project that focuses on the utility of metabolomics as a biomarker for OSA. Aims 1 and 3 leverages banked samples previously collected from subjects with and without OSA at the University of Pennsylvania and University of Iceland. Aim 2 is a prospective study that will collect serum samples from OSA subjects at the University of Pennsylvania and the University of Iceland.

Conditions

Obstructive Sleep Apnea

Talk to us

Study Overview

On this page

Study Details

Study overview

This is an R01 funded project that focuses on the utility of metabolomics as a biomarker for OSA. Aims 1 and 3 leverages banked samples previously collected from subjects with and without OSA at the University of Pennsylvania and University of Iceland. Aim 2 is a prospective study that will collect serum samples from OSA subjects at the University of Pennsylvania and the University of Iceland.

Metabolomics of Obstructive Sleep Apnea

Metabolomics of Obstructive Sleep Apnea

Condition
Obstructive Sleep Apnea
Intervention / Treatment

-

Contacts and Locations

Philadelphia

University of Pennsylvania, Philadelphia, Pennsylvania, United States, 19104

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Provision of signed and dated informed consent form
  • 2. Stated willingness to comply with all study procedures and availability for the duration of the study
  • 3. Male or female, aged 30-75 years old
  • 4. In good general health as evidenced by medical history and diagnosed with Obstructive Sleep Apnea (defined as AHI\>5)
  • 5. Ability to use accelerometer, perform Type 2 sleep test at home and agree to use PAP treatment.
  • 6. For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation.
  • 1. Current use of PAP treatment or mandibular advancement device or INSPIRE device
  • 2. Presence of active cancer treatment or heart failure (ejection fraction \<40%)
  • 3. Pregnancy or lactation
  • 4. Known allergic reactions to components of the plastic (used in PAP mask)
  • 5. Febrile illness within 2 weeks of signing consent
  • 6. Current drug or alcohol abuse
  • 7. Known diagnosis and treatment of diabetes because this will independently alter metabolomic results.
  • 8. Previously drawn laboratory Hemoglobin A1C above normal range (indicative of diabetes).

Ages Eligible for Study

30 Years to 75 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Pennsylvania,

Allan Pack, MBChB, PhD, PRINCIPAL_INVESTIGATOR, University of Pennsylvania

Aalim Weljie, PhD, PRINCIPAL_INVESTIGATOR, University of Pennsylvania

Study Record Dates

2025-12-31